Trial · NCT03651206
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
NCT03651206, Phase 2, Phase 3, Recruiting, ARCAGY/ GINECO GROUP
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib. Trials, record NCT03651206. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03651206
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
- NCT number
- NCT03651206
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 138 participants, estimated
- Lead sponsor
- ARCAGY/ GINECO GROUP
- Conditions
- Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
- Interventions
- Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
- First posted
- 2018-08-29
- Last updated
- 2026-09-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate (RR) at 4 months | 4 months after the last patient included | RR is defined as the proportion of patients with a partial response or complete response 4 months after randomization |
| Primary | Overall survival (OS) | 1 year after the last patient included | OS is the time from the date of the randomization until death due to any cause |
| Secondary | Progression Free Survival (PFS) | 1 year after the last patient included | PFS is the time from randomization to the date of event defined as the first documented progression (RECIST 1.1) or death due to any cause. |
| Secondary | Time To Subsequent Treatment (TTST) | 1 year after the last patient included | TTST is the time from the date of randomization to the earliest date of anti-cancer therapy start following study treatment discontinuation, or death by any cause in the absence of start of new anti-cancer therapy |
| Secondary | Progression-Free Survival 2 (PFS2) | 1 year after the last patient included | PFS2 is the time from the date of randomization to the second objective disease progression, or death from any cause, whichever occurs first. |
| Secondary | Objective Response Rate (ORR) | 1 year after the last patient included | ORR is the proportion of patients with a best response of Complete Response or Partial Response. |
| Secondary | Adverse events | 1 year after the last patient included | Assessed by CTCAE 5.0 |
| Secondary | Patient-reported outcomes (PROs) | 1 year after the last patient included | Assessed with questionnaires to be completed by patient and collected frequently during the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03651206
GET https://conductscience.org/api/trials/v1/NCT03651206/registered